Moderate‐To‐Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts
Hematological Oncology · 2025
DOI: 10.1002/hon.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Gaixiang Xu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Primary Myelofibrosis, Blast Crisis. Die Arbeit nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate‐to‐severe bone marrow fibrosis (MF). Among the patients with MDS, 347 (84%) had MF grade 0–1 (MF0–1), and 65 (16%) had MF grade 2–3 (MF2–3). Patients with MDS with MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; p = 0.34) but demonstrated inferior progression‐free survival (PFS) (6.6 vs. 15.2 months; p = 0.02) and a higher risk of leukemia transformation (35.4 vs. 16.4%; p < 0.001) compared to those with MF0–1. In the MDS with excess blast (MDS‐EB) subtypes, individuals with MF2‐3 exhibited shorter OS (4.8 vs. 11.7 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than those in patients with MF0‐1. However, individuals with MF0‐1 and MF2‐3 showed similar OS and PFS rates among the patients with the MDS non‐excess blast (MDS‐nonEB) subtypes. Additionally, we reclassified the patients with MDS according to the 2022 World Health Organization (WHO) classification. Patients with MDS with fibrosis (MDS‐f) had a shorter OS (5.6 vs. 13.8 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than MDS with increased blasts (MDS‐IB) subtypes. Our study reveals the unique features of patients with MDS‐MF2‐3 and validates the refinements made in the 5th edition of the WHO proposal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China.
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Zhejiang University, Hangzhou, China.
- Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China.
ORCID-Profile: Gaixiang Xu, Xinping Zhou, Liya Ma, Chen Mei, Yanling Ren, Jie Jin, Hongyan Tong
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, G., Ye, X., Zhang, Y., Wang, W., Zhu, S., Li, K., Zhou, X., Ma, L., Ye, L., Mei, C., Wang, L., Ren, Y., Jiang, L., Huang, J., Meng, H., Mai, W., Yu, W., Jin, J., & Tong, H. (2025). Moderate‐To‐Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts. Hematological Oncology. https://doi.org/10.1002/hon.70043
Vancouver
Xu G, Ye X, Zhang Y, Wang W, Zhu S, Li K, et al. Moderate‐To‐Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts. Hematological Oncology. 2025. doi:10.1002/hon.70043
BibTeX
@article{Xu2025,
author = {Xu, Gaixiang and Ye, Xingnong and Zhang, Yudi and Wang, Wei and Zhu, Shuanghong and Li, Kongfei and Zhou, Xinping and Ma, Liya and Ye, Li and Mei, Chen and Wang, Lu and Ren, Yanling and Jiang, Lingxu and Huang, Jian and Meng, Haitao and Mai, Wenyuan and Yu, Wenjuan and Jin, Jie and Tong, Hongyan},
title = {Moderate‐To‐Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70043}
}
EUVIMED